Prot #CBYL719XUS04T/NU 13B06: A Phase I Study of BYL719 and Trastuzumab-MCC-DM1 in HER2-Positive Metastatic Breast Cancer Patients with Progression on Prior Trastuzumab and Taxane-Based Therapy

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date2/4/141/31/17

    Funding

    • Novartis Pharmaceuticals Corporation (Prot #CBYL719XUS04T/NU 13B06)